MTOR and tuberous sclerosis: For example, the pivotal Examining Everolimus in a Study of Tuberous Sclerosis Complex (EXIST-3) trial demonstrated the efficacy of everolimus, a mammalian target of rapamycin (mTOR) inhibitor, in reducing seizure burden among patients with tuberous sclerosis complex (TSC).